Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ponesimod 20 mg in relapsing multiple sclerosis
2016-004719-10Phase 3Active
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jul 2017
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ponesimod in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Long-term safety of ponesimod 20 mg, Long-term tolerability of ponesimod 20 mg and 1 more. Started Jul 2017; status: active.
02
Drugs
ponesimod
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2016-004719-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004719-10.